

CURRICULUM VITAE

Radhika Kumari, M.D.

PERSONAL DATA

CURRENT POSITION: Radhika Kumari, MD
Clinical Associate Professor
Director of Transplant Outreach
Division of Gastroenterology and Hepatology,
Liver Transplant Program
Stanford University Medical Center

Office Address: 750 Welch Road, Suite 210
Palo Alto, CA 94304
Phone: 6504986080
Fax: 6504987888

E-MAIL rkumari@stanford.edu

Clinic Address: Hepatology and Liver Transplant Clinics
Stanford Boswell Clinics
300 Pasteur Drive
Palo Alto, CA, 94305

Stanford Outreach Clinics
750 Welch Road, Suite 215
Palo Alto, CA, 94304

FACULTY APPOINTMENTS

2007-2008 Clinical Instructor, Department of Internal Medicine & Division of
Gastroenterology and Hepatology
Saint Louis University Hospital, Missouri

2011-2013 Assistant Professor, Department of Gastroenterology
Loma Linda University, Loma Linda, California

2013-Present Clinical Associate Professor of Medicine
Division of Gastroenterology and Hepatology
Stanford University School of Medicine, Stanford, CA

EDUCATION

2003-2006 Internal Medicine Residency
Saint Louis University

2006-2007 Transplant Hepatology Fellowship
Saint Louis University

2008-2011 Gastroenterology Fellowship
Saint Louis University

RESEARCH/GRANTS:

Research grant: For travel to France for studying the immunohistochemical (IHC) staining pattern of Hepatic adenomas

CLINICAL RESEARCH:

STUDY: A Multi-center, Randomized, Placebo-Controlled, Double-Blind Study to Confirm the Efficacy and Safety of Terlipressin in Subjects with Hepatorenal Syndrome Type 1 (The Confirm Study)

ROLE: **Principal Investigator**

TYPE OF STUDY: Investigational Drug Study

FUNDING AGENCY: Mallinckrodt Pharmaceuticals

PLANNED NUMBER OF SUBJECTS: 10 subjects from Stanford and up to 300 subjects throughout the United States.

STUDY: A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis

ROLE: **Sub Investigator**

TYPE OF STUDY: Investigational Drug Study

FUNDING AGENCY: Intercept Pharmaceuticals

PLANNED NUMBER OF SUBJECTS: 10

STUDY: A 5-year Longitudinal Observational Study of Patients with Nonalcoholic Fatty Liver or Nonalcoholic Steatohepatitis

ROLE: **Sub Investigator**

TYPE OF STUDY: Observational Study/Registry

FUNDING AGENCY: Target Pharmsolution

PLANNED NUMBER OF SUBJECTS: 300

INVITED SPEAKER:

1. Management of Hepatocellular Carcinoma-2019
GI fellows Lecture Series
2. The multidisciplinary approach to HCC, how does the tumor board work-2019
San Mateo, CA
3. Management of Hepatitis c-Post AASLD conference-2018
DDCC-Digestive Health Conference Series
4. Management of Hepatitis C-2018
Regional Medical center of San Jose
5. Management of Acute liver failure-2018
O' Connor Hospital, San Jose
6. Staging and Treatment of HCC presented at Stanford GI/Liver Symposium-2016
St. Agnes Hospital, Fresno
7. Management of NASH-2016
San Pablo Health alliance
8. Portal Hypertension and Complications-2016
Internal Medicine Residents Lecture
9. Classification and Management of Hepatic Adenomas-2012
Loma Linda Medical Centre
10. Portal hypertension and its complications -2012
Indian Medical Association, Riverside
11. Correlations Utilizing A Recently Proposed Classification-2008
Presented at United States and Canadian academy of Pathology

12. Staging and Treatment of HCC presented a Stanford GI/Liver Symposium-2016
St. Agnes Hospital, Fresno

PUBLICATIONS:

1. Perumpail, B, Li, A, Cholankerik, G, **Kumari R**, Ahmed, A. Optimizing the Nutritional Support of Adult Patients in the Setting of Cirrhosis. *Nutrients* 2017; 9(10) 1114.
doi:10.3390/nu9101114
2. Aggarwal A, Yoo E, Perumpail, R, Cholankeril G, **Kumari R**, Daugherty T, Lapasaran A, Ahmed A. Sofosbuvir Use in the Setting of End-stage Renal Disease: A Single Center Experience. *J Clinical Transational Hep* 2017; 5(0) 00-00. doi: 10.14218 JCTH.2016.00060
3. Kutsenko A, Ladenheim, MR, Kim N, Nguyen P, Chen V, Jayasekera C, Yang JD, **Kumari R**, Roberts L. Increased Prevalence of Metabolic Risk Factors in Asian Americans With Hepatocellular Carcinoma. *J Clin Gastroenterol* 2017; 51(4):384-390
4. Chang Cy, Nguyen P, Le A, Zhao C, Ahmed A, Daugherty T, Garcia G, Lutchman G, **Kumari R**, Nguyen MH. Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease. *Medicine* 2017;96(6)
5. Lutchman G, Nguyen N, Chang C, Ahmed A, Daugherty T, Garcia G, **Kumari R**, Gupta S, Doshi D, Nguyen M. Effectiveness and tolerability of simeprevir and sofosbuvir in nontransplant and post-liver transplant patients with hepatitis C genotype 1. *Al Pharm & Therap Aug* 2016; 44(7)
6. Liu A, Perumpail RB, **Kumari R**, Younossi ZM, Wong RJ, Ahmed A. Advances in cirrhosis: Optimizing the management of hepatic encephalopathy. *World J Hepatol* 2015; 19;7(29):2871-9
7. Lutchman G, Nguyen N, Chang CY, Ahmed A, Daugherty T, Garcia G, **Kumari R**, Kim WR, Gupta S, Doshi D, Nguyen MH. Simeprevir (SMV) and Sofosbuvir (SOF) Without Ribavirin (RBV) for 12 Weeks for Genotype 1 Chronic Hepatitis C (CHC-1) With and Without Hepatic Decompensation: A Real-Life Single-Center Experience. *Gastroenterology* 2015 148(4): S1089
8. **Kumari R**, Nguyen MH. Interferon-free and ribavirin-free therapy for chronic hepatitis C genotype non-1. *J Clin Gastroenterol* 2015. *In press. (for invited review, we can write in press once invited)*
9. **Kumari R**, Nguyen MH. Fixed dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1. *Exp Opin Pharmacother.* 2015; 16(5):739-48.
10. 2015 DDW poster presentation: *Characteristics, Treatment Response, and Tolerability with Sofosbuvir (SOF)-Based and Simeprevir (SMV)-Based Direct Acting Antivirals (DAA) Therapies in Asians Versus Non-Asians*
11. Lutchman G, Nguyen N, Hsiao T, Vu V, Chen V, Ahmed A, Daugherty T, Barcia G, **Kumari R**, Kim WR, Nguyen MH. Safety and effectiveness of sofosbuvir (SOF) in combination with simeprevir (SIM) or ribavirin (RBV) for the treatment of hepatitis C virus (HCV) recurrence after liver transplant (LT) *Hepatology* 2014; 60 (Suppl): S670.
12. **Kumari R**, Kim WR, Coffee: A Panacea or Snake Oil for the Liver? *Clin Gastroenterol Hepatol.* 2014 Sep;12(9):1569-71

13. Antibiotic Prophylaxis among hospitalized End Stage Liver Disease patients with Model for End Stage Liver Disease score above 30 – Accepted to ACG 2013
14. Puri N, Mathur A, Lopez J, Patel B, **Kumari R.** A Comparative study of Argon Plasma Coagulation and Radiofrequency Ablation using HALO90 device for treatment for Gastric Antral Vascular Ectasia lesions. *Gastrointestinal Endoscopy* 2013;77 (5) Supp.
15. Liver transplantation in the setting of Nodular regenerative Hyperplasia-Accepted for ACG 2010
16. Prevalence of Viral Hepatitis and Hepatocellular carcinoma in Egypt – Presented at Seoul Liver symposium 2010

PROFESSIONAL SOCIETIES:

2008-present American Association for the Study of Liver Disease
 2008-present American Society for the Study for Gastrointestinal Endoscopy
 2008-present American College of Gastroenterology
 2008-present Northern California Gastroenterology Association, Vice President

COMMITTEES AND SERVICE:

2013-Present Liver Transplant Quality Council Committee, Board Member
 2013-Present Pediatric Liver Transplantation Transition Committee, Board Member
 2013-Present Pre Transplant PPEC Mortality Committee, Board Member
 2013-Present Fellows Clinical Competency Committee
 2016-Present Northern California Gastroenterology Association, Vice President

COMMITTEES AND SERVICE:

2006 American Board of Internal Medicine
 2011 American Board of Gastroenterology
 2014 Transplant Hepatology
 2003-2006 USMLE Part 1 -3

MEDICAL LICENSE:

1. Missouri Board of Registration for the Healing Arts
2. California Medical License